Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. It delivers programs and services to enhance the pharmaceutical supply chain for both human and animal health. The company distributes brand-name, specialty brand-name, and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies, and related services to healthcare providers in the U.S. and select global markets. Cencora also provides data analytics, outcomes research, and pharmaceutical consulting services. The company's strategy focuses on driving executional excellence in core distribution and investing in higher-margin adjacencies.

• Employees: 46,000+ (as of September 30, 2024)
• Geographic Footprint: 50+ countries
• Headquarters: Conshohocken, PA
• Founded: Not explicitly stated in the 10K
• Number of locations/facilities: Not explicitly stated in the 10K
• Revenue: $293.96 billion (FY2024)
• Market Capitalization: $29.55 billion (as of March 31, 2024)
• Key Subsidiaries/Brands: Alliance Healthcare, MWI Animal Health, World Courier, PharmaLex

• CEO: Robert P. Mauch
• Executive Chairman: Steven H. Collis
• CFO: James F. Cleary
• Chief Human Resources Officer: Silvana Battaglia
• Chief Legal Officer: Elizabeth S. Campbell

Key leaders have extensive experience in the pharmaceutical and healthcare industries. Robert P. Mauch has been with the company or its predecessors for over 25 years and became CEO in October 2024. Steven H. Collis has been with the company or its predecessors for over 25 years and became Executive Chairman in October 2024. James F. Cleary has been with the company or its predecessors for over 25 years and became CFO in November 2018. Silvana Battaglia joined the company in January 2019. Elizabeth S. Campbell joined the company in September 2021.

• Annual Revenue: $293.96 billion (FY2024)
• Net Income: $1.51 billion (FY2024)
• Market Cap: $29.55 billion (as of March 31, 2024)
• Total Assets: $67.1 billion (as of September 30, 2024)
• Employees: 46,000+ (as of September 30, 2024)
• Key Financial Highlights: Revenue increased by 12.1% YoY, Gross profit increased by 10.6% YoY, Operating income increased by 10.9% YoY (FY2024)

Cencora distributes a wide range of products and services, including:

• Pharmaceuticals: Brand-name, specialty brand-name, and generic pharmaceuticals.
• Healthcare Products: Over-the-counter healthcare products, home healthcare supplies, and equipment.
• Animal Health: Pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients.
• Consulting Services: Data analytics, outcomes research, reimbursement and pharmaceutical consulting services, and niche premium logistics.
• Manufacturer Services: Clinical trial support, product post-approval and commercialization support, and packaging solutions.

Cencora operates through two reportable segments:

• U.S. Healthcare Solutions: Distributes pharmaceuticals and related services to healthcare providers in the U.S., including hospitals, pharmacies, and physician practices. This segment also provides services to biotechnology and pharmaceutical manufacturers. Revenue for this segment was $265.34 billion in FY2024.
• International Healthcare Solutions: Focuses on international pharmaceutical wholesale and related service operations, primarily in Europe, and global commercialization services. This segment distributes pharmaceuticals and related services to healthcare providers, including pharmacies, doctors, and hospitals. Revenue for this segment was $28.63 billion in FY2024.

Cencora's strategy is focused on the global pharmaceutical supply chain, emphasizing:

• Core Distribution: Driving operational and capital efficiencies in its core distribution business in the U.S. and internationally.
• Higher-Margin Adjacencies: Investing in higher-margin, high-growth areas, such as solutions for pharmaceutical manufacturers and providers.
• Strategic Acquisitions: Pursuing acquisitions and investments to grow core offerings and enter related markets.
• Innovation: Driving innovative partnerships with manufacturers, providers, and pharmacies to improve product access and efficiency.

Cencora operates in the highly competitive pharmaceutical distribution and healthcare services industry. Key aspects of the industry include:

• Primary Industry: Pharmaceutical distribution and healthcare services.
• Market Trends: Growth in pharmaceutical sales, aging population, increased use of generic and biosimilar drugs, and increased use of drug therapies.
• Key Competitors: McKesson Corporation, Cardinal Health, Inc., and UPS Logistics.
• Market Position: One of the largest global pharmaceutical sourcing and distribution services companies.

• Customer Concentration: Loss or unfavorable renewal of contracts with key customers or group purchasing organizations.
• WBA Relationship: Failure to realize the anticipated benefits of the relationship with Walgreens Boots Alliance, Inc.
• Acquisitions and Investments: Risks associated with acquisitions and investments, including integration challenges and failure to achieve expected results.
• International Operations: Risks associated with international operations, including geopolitical risks, currency fluctuations, and compliance with foreign laws.
• Cybersecurity: Risks related to cybersecurity threats, data breaches, and disruptions to information systems.